DEALS: Digene shells out $1.6B for Qiagen


Digene shells out $1.6B for Qiagen


DEALS

WHO

WITH

WHAT

SCOOP

Digene

Qiagen

$1.6B acquisition

Analysts say the acquisition will give Qiagen a leg up in the expanding market for HPV testing.

Schering-Plough

Novacea

$440M collaboration pact

Schering-Plough has agreed to pay $60 million up front and take a stake in Novacea in exchange for commercialization rights to Asentar, a prostate cancer therapy currently in a late-stage trial.

Amgen

Ilypsa

$420M acquisition

Ilypsa is a private biotech that's been developing a new therapy for kidney disease.

Genzyme

Bioenvision

$345M buyout

The two companies co-developed clofarabin in Europe and Genzyme says that it has good reason to believe that the drug has great potential for other cancer indications.

Amgen

Alantos

$300M acquisition

Alantos' lead drug candidate--ALS 2-0426--is a DPP-IV inhibitor in Phase IIa, a popular approach to treating Type 2 diabetes.

Suggested Articles

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.